CXCL13 has been shown to be useful to monitor clinical progression and response to treatment in particularly in Lyme disease, anti-NMDAR encephalitis, multiple sclerosis and B cell lymphoproliferative disorders [21, 25–28]. Here, CXCL13 is linked to encephalitis.